

Proventus
Making Life Fairer
Help-

Working together to make a difference
Find Us Here
If you have experienced any adverse side effects from a medication or therapy -
Side effects may occur
Phase II trial results were published in 2006 involving two different doses of Teriflunomide
over 36 weeks in a trial involving 179 people with relapsing remitting MS, 157 people
with secondary progressive MS who still experience relapses and 22 who received placebo.
MRI brain scans were performed every 6 weeks.
Both doses of drug tested in the study were associated with reduced numbers of active MRI lesions.
Fewer people receiving the higher dose of Teriflunomide demonstrated disability increase compared to placebo. No effect on relapse rate was observed.
One phase III study called TEMSO involving 870 people with MS, assessing if teriflunomide is able to reduce the frequency of relapses and the accumulation of disability began in Sept 2004 and was completed in June 07.
The results have not yet been published. ClinicalTrials.gov Identifier NCT00134563
Another
world-
This began in February 2008. ClinicalTrials.gov Identifier: NCT00622700
Other phase
II studies are assessing the effects of teriflunomide in conjunction with beta interferon
therapies.